The Biological Disease-Modifying Antirheumatic Drugs and the Risk of Cardiovascular Events: A Systematic Review and Meta-Analysis

<table class="figure-group"><tr class="fig-image" id="a"><td><object data="https://static.hindawi.com/articles/mi/volume-2021/7712587/figures/7712587.fig.002a.svgz" name="7712587.fig.002a" type="image/svg+xml"></object></td></tr><tr class="fig-caption"><td><b>(a) </b>Myocardial infarction</td></tr><tr class="fig-image" id="b"><td><object data="https://static.hindawi.com/articles/mi/volume-2021/7712587/figures/7712587.fig.002b.svgz" name="7712587.fig.002b" type="image/svg+xml"></object></td></tr><tr class="fig-caption"><td><b>(b) </b>Heart failure</td></tr><tr class="fig-image" id="c"><td><object data="https://static.hindawi.com/articles/mi/volume-2021/7712587/figures/7712587.fig.002c.svgz" name="7712587.fig.002c" type="image/svg+xml"></object></td></tr><tr class="fig-caption"><td><b>(c) </b>Cardiovascular death</td></tr><tr class="fig-image" id="d"><td><object data="https://static.hindawi.com/articles/mi/volume-2021/7712587/figures/7712587.fig.002d.svgz" name="7712587.fig.002d" type="image/svg+xml"></object></td></tr><tr class="fig-caption"><td><b>(d) </b>All-cause mortality</td></tr></table>

<div>The associations between the use of bDMARD and cardiovascular endpoint.</div>

Mediators of Inflammation

fig2

Figure 2

Figure 2: The Biological Disease-Modifying Antirheumatic Drugs and the Risk of Cardiovascular Events: A Systematic Review and Meta-Analysis 